[{"id":"2ec7b800-d439-4f02-9434-501fd48a1955","acronym":"","url":"https://clinicaltrials.gov/study/NCT03320330","created_at":"2023-10-09T08:13:27.513Z","updated_at":"2024-07-02T16:35:34.579Z","phase":"Phase 1/2","brief_title":"Pepinemab in Treating Younger Patients With Recurrent, Relapsed, or Refractory Solid Tumors","source_id_and_acronym":"NCT03320330","lead_sponsor":"Children's Oncology Group","biomarkers":" SEMA4D","pipe":"","alterations":" ","tags":["SEMA4D"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e pepinemab (VX15)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 26","initiation":"Initiation: 01/31/2018","start_date":" 01/31/2018","primary_txt":" Primary completion: 12/31/2020","primary_completion_date":" 12/31/2020","study_txt":" Completion: 09/22/2024","study_completion_date":" 09/22/2024","last_update_posted":"2023-10-05"},{"id":"93cd4056-cbe5-452e-bdc9-f1bda3f5e8fd","acronym":"","url":"https://clinicaltrials.gov/study/NCT03268057","created_at":"2021-01-17T17:42:36.938Z","updated_at":"2025-02-25T16:06:50.261Z","phase":"Phase 1b","brief_title":"VX15/2503 in Combination With Avelumab in Advanced Non-small Cell Lung Cancer","source_id_and_acronym":"NCT03268057","lead_sponsor":"Vaccinex Inc.","biomarkers":" KRAS • ALK • ROS1 • SEMA4D","pipe":" | ","alterations":" KRAS mutation • EGFR mutation • ALK rearrangement","tags":["KRAS • ALK • ROS1 • SEMA4D"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e KRAS mutation • EGFR mutation • ALK rearrangement"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Bavencio (avelumab) • pepinemab (VX15)"],"overall_status":"Completed","enrollment":" Enrollment 62","initiation":"Initiation: 10/05/2017","start_date":" 10/05/2017","primary_txt":" Primary completion: 09/09/2020","primary_completion_date":" 09/09/2020","study_txt":" Completion: 09/10/2020","study_completion_date":" 09/10/2020","last_update_posted":"2022-05-02"}]